hVIVO Reshapes Clinical Platform as 2025 Profits Slide on Sector Headwinds

The latest announcement is out from Open Orphan Plc ( (GB:HVO) ).

hVIVO reported a sharp drop in 2025 revenue to £46.8 million from £62.7 million and a fall in adjusted EBITDA to £1.4 million, reflecting a transitional year and wider macro headwinds across pharmaceutical services. Profitability and cash balances were significantly lower, but the group exited the year with a £30 million contracted orderbook and expects high single‑digit revenue growth in 2026, weighted to the second half.

Operationally, the company completed the acquisition and integration of two German Clinical Research Units from CRS and the UK‑based Cryostore, extending into early‑phase trials, cardiometabolic and immunology studies, and temperature‑controlled storage. hVIVO has reorganised into four integrated service lines, validated a new hMPV challenge model, secured multi‑site trial contracts and an influenza challenge study for Traws Pharma, and rebranded legacy units under a single hVIVO identity, positioning itself as a diversified early‑stage development partner rather than a pure human challenge trials CRO.

Management emphasised that the broadened platform and cross‑selling between UK and German sites should reduce dependence on infectious disease challenge work and support margin recovery. A strong pipeline across all business lines, along with ongoing discussions for additional human challenge trial contracts, underpins the company’s view that its expanded, integrated model offers multiple avenues for long‑term growth and enhanced industry positioning.

The most recent analyst rating on (GB:HVO) stock is a Buy with a £10.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.

Spark’s Take on HVO Stock

According to Spark, TipRanks’ AI Analyst, HVO is a Outperform.

Open Orphan Plc’s overall stock score is driven by strong financial performance and attractive valuation. The company’s robust revenue growth and low leverage position it well in the biotechnology sector. While technical indicators show bullish momentum, the stock is trading below key moving averages, suggesting potential resistance. The low P/E ratio and reasonable dividend yield enhance its attractiveness to value and income investors.

To see Spark’s full report on HVO stock, click here.

More about Open Orphan Plc

hVIVO plc is a UK‑based, full‑service international clinical development partner and the global leader in human challenge trials, working with seven of the world’s ten largest biopharma companies. The group provides an end‑to‑end platform spanning preclinical strategy, first‑in‑human studies, Phase II patient trials and specialist virology and immunology lab services across owned sites in the UK and Germany.

Its four integrated service lines – Consulting, Clinical Trials, Human Challenge Trials and Laboratories – are designed to accelerate clients’ path to clinical proof‑of‑concept. hVIVO’s capabilities include a large participant database, Europe’s largest specialist recruitment platform FluCamp, and the world’s largest quarantine facility for controlled viral exposure studies in London.

Average Trading Volume: 3,367,043

Technical Sentiment Signal: Sell

Current Market Cap: £50.94M

See more insights into HVO stock on TipRanks’ Stock Analysis page.